Tom 14, Nr 2 (2018)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2018-08-08
Wyświetlenia strony
1485
Wyświetlenia/pobrania artykułu
2425
Rekomendacje interdyscyplinarnej grupy ekspertów w zakresie kompleksowego i długofalowego leczenia spastyczności toksyną botulinową typu A
Pol. Przegl. Neurol 2018;14(2):47-59.
Streszczenie
Skuteczność i bezpieczeństwo leczenia spastyczności iniekcjami toksyny botulinowej są dobrze udokumentowane. Terapia ta, objęta w Polsce programem lekowym, należy dziś do standardu w leczeniu powikłań ruchowych po udarze mózgu. Autorzy niniejszych rekomendacji przedstawiają w interdyscyplinarny sposób poglądy na wybrane zagadnienia: leczenie innych etiologicznie form spastyczności, skuteczność długofalowego podawania toksyny botulinowej, bezpieczeństwo stosowania większych dawek leku w kontekście jednoczesnego leczenia spastyczności zarówno kończyny górnej, jak i dolnej, różnice w dawkowaniu poszczególnych postaci leku, zalecenia związane z prowadzeniem rehabilitacji w trakcie terapii, rekomendacje międzynarodowych i narodowych grup ekspertów w tym zakresie.
Słowa kluczowe: spastycznośćudar mózgutoksyna botulinowa
Referencje
- Sławek J. Toksyna botulinowa w leczeniu spastyczności kończyny górnej. Pol Przegl Neurol. 2015; 11(4): 190–20.
- Sławek J, Bogucki A, Budrewicz S, et al. Leczenie toksyną botulinową spastyczności kończyny dolnej po udarze mózgu — rekomendacje Sekcji Schorzeń Pozapiramidowych Polskiego Towarzystwa Neurologicznego, Polskiego Towarzystwa Choroby Parkinsona i Innych Zaburzeń Ruchowych oraz Interdyscyplinarnej Grupy Ekspertów. Pol Przegl Neurol. 2016; 12(2): 65–79.
- Gracies JM, Brashear A, Jech R, et al. International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015; 14(10): 992–1001.
- Safarpour Y, Mousavi T, Jabbari B. Botulinum toxin treatment in multiple sclerosis — a review. Curr Treat Options Neurol. 2017; 19(10): 33.
- Wissel J, Bensmail D, Ferreira JJ, et al. TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88(14): 1321–1328.
- Sławek J, Car H, Bonikowski M, et al. [Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications]. Neurol Neurochir Pol. 2010; 44(1): 43–64.
- Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009; 41(1): 13–25.
- Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. RCP, London 2009.
- Sheean G, Lannin NA, Turner-Stokes L, et al. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010; 17(Suppl 2): 74–93.
- Baker JA, Pereira G. The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the grades of recommendation, assessment, development and evaluation approach. Clin Rehabil. 2013; 27(12): 1084–1096.
- Wissel J, Ganapathy V, Ward AB, et al. OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: findings from a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 2016; 52(1): 17–26.
- Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19): 1818–1826.
- Gracies JM, Esquenazi A, Brashear A, et al. International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: randomized trial and extension. Neurology. 2017; 89(22): 2245–2253.
- Grigoriu AI, Dinomais M, Rémy-Néris O, et al. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch Phys Med Rehabil. 2015; 96(11): 2067–20678.e1.
- Bakheit AMO, Fedorova NV, Skoromets AA, et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry. 2004; 75(11): 1558–1561.
- Gordon MF, Brashear A, Elovic E, et al. BOTOX Poststroke Spasticity Study Group. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004; 63(10): 1971–1973.
- Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43(6): 486–492.
- Lagalla G, Danni M, Reiter F, et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehab. 2000; 79(4): 377–384.
- Gracies JM, O'Dell M, Vecchio M, et al. International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group. Effects of repeated abobotulinumtoxinA injections in upper limb spasticity. Muscle Nerve. 2018; 57(2): 245–254.
- Schramm A, Ndayisaba JP, Auf dem Brinke M, et al. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm (Vienna). 2014; 121(5): 521–530.
- Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006; 13(Suppl 1): 11–15.
- Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: a systematic review and meta-analysis. Neurotox Res. 2016; 29(1): 105–117.
- Naumann M, Boo LM, Ackerman AH, et al. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013; 120(2): 275–290.
- Dressler D, Adib Saberi F, Bigalke H. IncobotulinumtoxinA (Xeomin(®)) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(®)). J Neural Transm (Vienna). 2014; 121(7): 769–771.
- Rosales RL, Efendy F, Teleg ESa, et al. Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: a meta-analysis. J Neurol Sci. 2016; 371: 6–14.
- Esquenazi A, Albanese A, Chancellor MB, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013; 67: 115–128.
- Santamato A. Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity. Neuropsychiatr Dis Treat. 2016; 12: 251–263.
- Wein T, Esquenazi A, Jost WH, et al. OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized trial. PM R. 2018 [Epub ahead of print].
- Santamato A, Panza F, Intiso D, et al. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017; 378: 182–186.
- Baricich A, Grana E, Carda S, et al. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna). 2015; 122(9): 1283–1287.
- Henzel MK, Munin MC, Niyonkuru C, et al. Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections. PM R. 2010; 2(7): 642–646.
- Picelli A, Baricich A, Cisari C, et al. The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A. Funct Neurol. 2017; 32(2): 89–96.
- Santamato A, Micello MF, Ranieri M, et al. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. J Neurol Sci. 2015; 350(1-2): 1–6.
- Giovannelli M, Borriello G, Castri P, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007; 21(4): 331–337.
- Mills PB, Finlayson H, Sudol M, et al. Systematic review of adjunct therapies to improve outcomes following botulinum toxin injection for treatment of limb spasticity. Clin Rehabil. 2016; 30(6): 537–548.
